Therapy of malignant glioma relies on treatment with the O 6 -methylating agent temozolomide (TMZ) concomitant with ionizing radiation followed by adjuvant TMZ. For the treatment of recurrences, DNA chloroethylating drugs are also used. The main killing lesion induced by these drugs is O 6 -alkylguanine. Since this damage is repaired by O 6 -methylguanine-DNA methyltransferase (MGMT), the repair enzyme represents a most important factor of drug resistance, limiting the therapy of malignant high-grade gliomas. Although MGMT has been shown to be transcriptionally up-regulated in rodents following genotoxic stress, it is still unclear whether human MGMT is subject to up-regulation. Here, we addressed the question whether MGMT in glioma cells is enhanced following alkylating drugs or ionizing radiation, using promoter assays. We also checked the response of glioma cell lines to dexamethasone. In a series of experiments, we found no evidence that the human MGMT promoter is significantly up-regulated following treatment with TMZ, the chloroethylating agent nimustine or radiation. It was activated, however, by dexamethasone. Using deletion constructs, we further show that the basal level of MGMT is mainly determined by the transcription factor SP1. The high amount of SP1 sites in the MGMT promoter likely prevents transcriptional up-regulation following genotoxic stress by neutralizing inducible signals. The regulation of MGMT by miRNAs plays only a minor role, as shown by DICER knockdown experiments. Since high dose dexamethasone concomitant with temozolomide is frequently used in glioblastoma therapy, induction of the MGMT gene through glucocorticoids in MGMT promoter unmethylated cases might cause further elevation of drug resistance, while radiation and alkylating drugs seem not to induce MGMT at transcriptional level.
High-grade gliomas (HGG) comprise WHO grade III and grade IV tumors. Glioblastomas (GB) (WHO grade IV) account for 60-70%, while anaplastic astrocytomas (AA) and anaplastic oligodendrogliomas together with anaplastic oligoastrocytomas account for 20-25% of HGG (Louis et al. 2016) . Despite intensive therapy, patients suffering from GB have a dismal prognosis with 14.6 months median survival and a 2-year survival rate of less than 26.5% (Stupp et al. 2005) . Treatment of HGG consists of maximum safe resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ, temodal) (Stupp et al. 2009 ). Furthermore, the DNAchloroethylating nitrosoureas lomustine (CCNU), nimustine (ACNU), carmustine (BCNU), or fotemustine are used for treatment of recurrences. TMZ is a potent inducer of apoptosis through the induction of O 6 -methylguanine (O 6 MeG) (Kaina et al. 1997) while CNU induces apoptosis by generating O 6 -chloroethylguanine (O 6 ClG) (Ludlum 1997) . Both lesions are repaired by the DNA repair protein O 6 -methylguanine-DNA methyltransferase (MGMT) (Pegg 2000) .
In the absence of MGMT, O 6 MeG leads via futile mismatch repair cycles to persisting single-strand gaps (Mojas et al. 2007 ) and, following replication, to DNA double-strand breaks (Quiros et al. 2010) . O 6 ClG undergoes intramolecular rearrangement forming N1-O 6 -ethenoguanine and finally N1-guanine-N3-cytosine interstrand crosslinks (Tong et al. 1982; Fischhaber et al. 1999) . These give rise to replication blockage and DSBs, which represent the ultimate trigger of cell death by apoptosis upon treatment with TMZ or CNU . Following the repair reaction MGMT becomes inactivated, ubiquitinated, and finally proteosomally degraded (Xu-Welliver and Pegg 2002) . The amount of MGMT per cell is an important determinant for the ability of cancer cells to evade alkylating agent induced cell death (Hermisson et al. 2006) , and strongly impacts the success of anticancer therapy (Wiewrodt et al. 2008) .
About 20% of primary glioblastomas lack MGMT activity (Wiewrodt et al. 2008) and about 40% display CpG methylation in specific islands of the promoter (Esteller et al. 2000) . Thus, epigenetic silencing plays a key role in regulation of this repair gene in gliomas. Since MGMT promoter methylation correlates with enhanced overall survival and progression-free survival, the methylation status of MGMT is used as a predictive marker in glioblastoma therapy (Hegi et al. 2005; Stupp et al. 2009; Switzeny et al. 2016) . If not silenced by promoter methylation, MGMT expression and activity is highly variable between individuals, organs and normal and tumor cells (Christmann et al. 2011 ).
An important question is whether MGMT expression can be enhanced by anticancer therapy through promoter activation. In rodents, transcriptional up-regulation of MGMT was reported following treatment with corticosteroids, UVC light, ionizing radiation, and alkylating agents (Fritz et al. 1991; Grombacher and Kaina 1995; Grombacher et al. 1996; Rafferty et al. 1996) . Although human diploid fibroblasts and HeLa cells were shown not to be able to up-regulate MGMT following genotoxic stress (Fritz et al. 1991) , the question remained open whether MGMT in human brain cancer cells can be transcriptionally up-regulated during therapy with corticosteroids, alkylating anticancer drugs, or radiotherapy.
The human MGMT promoter is 2714 bp in length and several potential transcription factor binding sites within the promoter have been identified (Harris et al. 1991) . The human promoter harbors two AP-1 sites, two NF-jB sites, two glucocorticoid responsive elements (GRE), and up to 20 specificity protein 1 (SP1) sites, all of which might be targets for activation (Christmann and Kaina 2013) . It was shown that the human MGMT promoter can be activated by either co-expression of c-Fos/c-Jun in the mouse F9 teratocarcinoma cell line or by the NF-jB subunit p65 (Boldogh et al. 1998; Lavon et al. 2007) . Furthermore, treatment with N-methyl-N'-nitro-N-nitrosoguanidine, methyl methanesulfonate, ionizing radiation (IR), or dexamethasone slightly enhanced the activity of the human promoter transfected in rat hepatoma cells (Grombacher et al. 1996) . In HeLa cells, dexamethasone was found to increase MGMT expression via activation of two putative glucocorticoid responsive elements (Biswas et al. 1999) . Glucocorticoids are frequently used in glioblastoma therapy for treating edema, which occur after resection of the tumor and radiation/temozolomide therapy and also during pseudoprogression. In these cases, high doses of glucocorticoids such as dexamethasone are used over a period of weeks, often together with adjuvant temozolomide (Brandsma et al. 2008; Deutsch et al. 2013) . The endogenous MGMT mRNA expression was also enhanced in HeLa S3 cells after treatment with the PKC activators TPA (12-O-Tetradecanoylphorbol-13-acetate = PMA, phorbol-12-myristate-13-acetate) or DAG (diacylglycerol) (Boldogh et al. 1998) . Moreover, it has been shown that MGMT is regulated via the Wnt/b-catenin pathway (Wickstrom et al. 2015) . In conclusion, although research on the regulation of MGMT dates back to more than 30 years, it is still unclear what the key mechanisms are that cause the variation in MGMT activity and its possible induction following genotoxic stress in human normal and cancer cells, notably glioblastomas. The purpose of this study was to prove or disprove transcriptional activation of the MGMT promoter in glioblastoma cells, using a panel of well-characterized cell lines, treated with IR, glucocorticoids or alkylating anticancer drugs.
Material and methods
The study was not pre-registered and no blinding, group assignment, or randomization procedures were necessary nor applied in the experiments.
Cloning of the MGMT promoter
The human MGMT promoter (NG_052673, À2591 bp to +123 bp) (Harris et al., 1991) was cloned into the multiple cloning site of the luciferase reporter plasmid pGL4.10 (luc2) via the restriction enzymes KpnI and SacI. Based on this construct, the MGMT promoter DSP1 was constructed via a truncated PCR product, which integrated a SacI restriction site 259 bp upstream of the transcription start of the MGMT gene. With the restriction enzymes PmlI (cutting on the MGMT promoter) and SacI (cutting on the pGL4 plasmid) the PCR-product was cloned into the MGMT promoter pGL4 and therefore deleted the last 319 bp of the MGMT promoter. All constructs were verified by sequencing. The primers used for cloning are listed in Table S1 .
Cell culture U87 cells were purchased from Cell Line Service (Eppelheim, Germany) and the glioblastoma cell line LN229 (RRID: CVCL_0393) was obtained from LGC Standards (Wesel am Rhein, Germany). The glioblastoma cell lines T98G (RRID:CVCL_0556), LN18 (RRID:CVCL_0392), A172 (RRID:CVCL_0131), D247 (RRID:CVCL_1153), LN308 (RRID:CVCL_0394), LN319 (RRID:CVCL_3958), U118 (RRID:CVCL_0633), U138 (RRID: CVCL_0020), U251 (RRID:CVCL_0021), U343 (RRID: CVCL_S471), and U373 (RRID:CVCL_2219) cells were kindly provided by Prof. Weller (Laboratory of Molecular NeuroOncology, University Hospital and University of Zurich, Switzerland) and were characterized previously (Wischhusen et al. 2003) . MO59K and MO59J cells were a kind gift from Dr. M. Rave-Fr€ ank (University Medical Centre Gottingen, G€ ottingen, Germany) and were described previously Of note, among the cell line used in this study LN229 and U373 are listed as an eventually misidentified cell line by the International Cell Line Authentication Committee (ICLAC). Thus, for U373 a potential confusion with the glioblastoma cell line U-251 and for LN319 a confusion with a subline of the glioblastoma cell line LN-992 has been reported. However, since comparison between the different cell lines was not performed, even potential contaminations with other glioblastoma cell lines would not affect the conclusions drawn in the present manuscript.
Dual luciferase/promoter activity assay Analysis was performed using the dual luciferase assay from Promega via luminometric measurement. In this assay, the MGMT promoter-luc construct was co-transfected with a renilla-luciferase reporter plasmid (pRL-EF1a), which was used as internal control for the efficiency of transfection. For details, see Appendix S1.
Cell transfection and knock down
For the dual luciferase assay, cells were transfected in 24-well plates with Effectene (Qiagen, Valencia, CA, USA) according to manufacturer's protocol. The siRNA knock down of dicer (sc-40489; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and SP1 (sc-29487; Santa Cruz) was performed using lipofectamine (Invitrogen, Carlsbad, CA, USA) for transfection as described in the working manual.
Western blotting
Whole cell extracts were analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and semi-dry western blotting on nitrocellulose membranes. The protein-antibody complexes were visualized via enhanced chemiluminescence reaction. The antibodies and dilutions used are listed in Table S2 .
Preparation of RNA, semi-quantitative PCR and RT qPCR Total RNA and microRNA were isolated using the Nucleo Spin RNA Kit (Machery and Nagel, D€ uren, Germany) and the Nucleo Spin microRNA Kit (Machery and Nagel) respectively. One microgram of total RNA was transcribed into cDNA (Verso cDNA Kit; Thermo Scientific, Darmstadt, Germany); 200 ng of microRNA were transcribed into cDNA (miScript II RT Kit; Qiagen). qPCR was performed using the SensiMix TM SYBR Green & Fluorescein Kit (Bioline, Luckenwalde, Germany) or the miScript SYBR Green PCR Kit (Qiagen). The primers used are listed in Table S1 . The researched microRNA was miR181d (miScript Primer Assay miR181d; Qiagen). The microRNA 0 s miRNU6 (miScript Primer Assay miRNU6; Qiagen) and miRSNORD68 (miScript Primer Assay miRSNORD68; Qiagen) were used as reference microRNA 0 s.
Radioactive MGMT activity assay, promoter methylation-specific PCR and HRM analysis MGMT activity of 17 glioblastoma cell lines was determined as described (Christmann et al. 2011) . Promoter methylation-specific PCR of 17 glioblastoma cell lines was performed as described previously (Christmann et al. 2010) . Quantitative high resolution melt (HRM) analysis was performed as described (Switzeny et al. 2016) .
Statistical analysis
For promoter activity assay and qPCR, data were analyzed using Student's unpaired two-tailed t-test on the basis of a difference between sample means. In all cases, three independent experiments (n = 3) were performed. Calculations were performed using the GraphPad Prism (version 6.01) software; GraphPad Software Inc., San Diego, CA, USA (*p < 0.05, **p < 0.01, ***p < 0.001).
Absence of an asterisk indicates there is no statistical difference. Correlation between MGMT and SP1 expression was calculated using GraphPad Prism version 6.0c for Mac by the use of the Pearson correlation coefficient.
Results

Transcriptional regulation of MGMT by TPA and dexamethasone
The human MGMT promoter (base À2591 to +123) was cloned into the luciferase reporter plasmid pGL4 and its activity was determined in MGMT proficient (GBP61, LN18, T98G) and deficient (LN229, U87) glioblastoma cell lines, using the dual luciferase reporter assay. The MGMT proficient cervix carcinoma cell line HeLa S3 was included in these experiments, since regulation of MGMT was intensively studied in this cell line. The basic MGMT promoter activity was normalized to the promoter activity of a control plasmid harboring the SV40 promoter (pGL2) and a negative control without promoter (pGL4). As shown in Fig. 1a , all glioblastoma cell lines used in this study displayed activity of the transfected MGMT promoter although their MGMT expression status was different (see Figure S1 ). This shows that MGMT promoter methylation has no influence on the expression of transcription factors regulating MGMT.
To check whether the GREs and AP-1 sites confer upregulation of the MGMT promoter, we assessed the promoter activity following treatment with the glucocorticoid dexamethasone or the PKC activator TPA, which induces AP-1 activity. A significant up-regulation of the promoter activity was observed in dexamethasone-treated glioblastoma cells (Fig. 1b) . Following treatment with the PKC activator TPA, a tendency towards up-regulation was observed in LN18, T98G, and HeLa S3 cells, which was however not significant.
Transcriptional regulation of MGMT by anticancer drugs and ionizing radiation
Glioblastoma therapy is based on treatment with TMZ, nitrosoureas (e.g. nimustine) and IR. Although IR is a wellknown activator of AP-1 and NF-jB signaling in various cell MGMT promoter activity after treatment with TPA (200 ng/mL) and DMSO (solvent for TPA). (a-c) Data are presented as mean AE SEM from three independent biological replicates (n = 3). Data were analyzed using Student's unpaired twotailed t-test (*p < 0.05, **p < 0.01, ***p < 0.001), absence of an asterisk indicates there is no statistical difference. Under (a), in all cell lines, the differences between the promoter activity of the empty pGL4 and the MGMT-promoter pGL4 constructs are statistically different (p < 0.001).
systems, including glioma (Chastel et al. 2004) , only limited data are available concerning activation of these transcription factors by TMZ and nitrosureas. In our previous work we showed that following TMZ and nimustine treatment AP-1 signaling was clearly activated in glioma cells (Tomicic et al. 2015) . Moreover, enhanced NF-jB activity was observed upon TMZ exposure (Christmann et al. 2017) . Therefore, we supposed that, similar to rat hepatoma cells, these treatments may activate MGMT expression in AP-1 or NF-jBdependent manner. However, neither TMZ nor nimustine activated significantly the human MGMT promoter (Fig. 2a  and b) . Interestingly, a weak but significant induction was observed upon treatment with to O 6 BG used either alone or in combination with TMZ or nimustine ( Fig. 2a and 2b ). On opposite, IR even had a negative impact on MGMT promoter activity (Fig. 2c ). The expression of the endogenous MGMT was also not enhanced after treatments with alkylating agents and IR, neither on mRNA nor on protein level ( Figure S2a and b for GBP61 and data not shown). Collectively, the data suggest that MGMT is not subject to transcriptional upregulation in human glioblastoma cells following treatment with TMZ, the nitrosoureas or IR.
Basal expression of MGMT
We also wished to address the question of why MGMT is heterogeneously expressed in glioma cells independent of MGMT promoter methylation. Therefore, we determined in parallel promoter methylation, MGMT mRNA and MGMT protein expression as well as MGMT activity in a panel of 18 glioma cell lines ( Figure S1 ). This study revealed a great variability in promoter methylation, MGMT mRNA and MGMT protein expression and activity between the cell lines. Overall, there was a high correlation between MGMT mRNA, MGMT protein expression and activity in each line, indicating that the observed differences in MGMT enzyme activity are based on altered transcription and not altered protein synthesis or posttranslational modification.
Impact of miRNAs on basal MGMT expression
A mechanism that has been reported to impact MGMT mRNA expression is miRNA-mediated repression, notably via miR181d (Zhang et al. 2012) . To analyze whether miR181d affects MGMT expression in glioma cells, we compared the expression of endogenous MGMT mRNA with the expression of miR181d in eight glioma cell lines characterized by lack of promoter methylation. The data showed a weak negative correlation of miR181d with MGMT expression (Fig. 3a and Figures S1 and S3a) . To analyze whether other miRNAs than miR181d are directly or indirectly involved in the regulation of MGMT, we knocked down the Dicer, which is a key protein in the regulation of miRNAs, in the glioblastoma cell line LN18. As shown by western blot analysis (Fig. 3b) , the Dicer was down-regulated 48 h following siRNA treatment and stayed repressed up to 120 h after transfection. qPCR analysis revealed that under these conditions miR181d expression was strongly down-regulated (measured 48 up to 120 h after siRNA transfection) (Fig. 3c) . Despite significant down-regulation of miR181d, only a slight increase in the MGMT mRNA expression level was observed after dicer knockdown (Fig. 3d) . In line with this, transfection with a synthetic miR181d only slightly reduced the MGMT mRNA level in LN18 cells (Fig. 3e) . The data let us to conclude that miRNAs have only a low impact on MGMT mRNA level and thus play only a minor role in regulating the basal expression of MGMT in glioma cells. was measured upon non-silencing siRNA (ns) and siDicer transfection in LN18 cells by qPCR (d) Expression of endogenous MGMT was measured upon non-silencing siRNA (ns) and siDicer transfection in LN18 cells by qPCR. (e) Expression of endogenous MGMT was measured upon mimic miR181d (mimic) transfection in LN18 cells by qPCR. (c-e) Data are presented as mean AE SEM from three independent biological replicates (n = 3). Data were analyzed using Student's unpaired two-tailed t-test (**p < 0.01, ***p < 0.001), absence of an asterisk indicates there is no statistical difference.
Impact of SP1 on basal MGMT expression
MGMT is controlled by a strong promoter. Its activity is even higher than the activity of the SV40 promoter, which is often used as positive control (see Fig. 1a ). The high activity of the MGMT promoter could be explained by the large number of SP1 binding sites clustered near to the transcription start site of the MGMT gene (Fig. 4a) . To analyze the impact of SP1 binding sites on basal MGMT activity, we generated a human MGMT promoter deletion mutant (MGMTDSP1). The mutant lacks 319 bp of the full length MGMT promoter (Fig. 4a) , thereby it is missing most of the SP1 binding sites downstream of the second NFjB binding site. After transfection in glioblastoma cells, the promoter activity of MGMTDSP1 was compared with the wt MGMT promoter. Deletion of the SP1 binding sites led to a significant decrease (200-400-fold) of the promoter activity, but did not cause Basic promoter activity of the MGMT-promoter DSP1 construct upon transfection into the cell lines LN229, U87, GBP61, LN18, T98G, and HeLa S3 was measured by dual luciferase assay in comparison to the MGMT-promoter construct (normalized to 10 RLU luc/RLU ren) and the negative control (pGL4). Data are presented as mean AE SEM from three independent biological replicates (n = 3). Data were analyzed using Student's unpaired two-tailed t-test. In all cell lines, the differences between the MGMT-promoter and the MGMTpromoter DSP1 constructs are statistically different (p < 0.001). (c) Correlation of endogenous MGMT expression with SP1 in eight MGMT expressing glioblastoma cell lines (D247, GBP44, T98G, M059K, GBP61, M059J, LN18, U118) was calculated using GraphPad Prism version 6.0c for Mac, by the use of the Pearson correlation coefficient. (d) Expression of endogenous MGMT and SP1 in the glioma cell lines GBP44, GBP61, M059K, M059J, T98G, D247, U118, and LN18 was detected by immunodetection. (e) Expression of endogenous SP1 and MGMT was analyzed in T98G cells after transfection with siRNA against SP1 (si) or non-silencing siRNA (ns) by immunodetection. GAPDH was used as internal loading control.
complete promoter silencing (Fig. 4b) . These data show that SP1, but not other transcription factors, play a major role in basal MGMT regulation (of a non-methylated promoter).
To substantiate the hypothesis that SP1 is indeed the major player regulating basal MGMT expression in glioblastoma cells, the level of MGMT mRNA and SP1 protein were compared in eight MGMT-proficient glioma cell lines. The data show that the expression of MGMT mRNA was significantly correlated with SP1 protein expression (Fig. 4c) . We also compared the expression of MGMT and SP1 on protein level and show that cell lines expressing a large amount of SP1 (U118, LN118) display high MGMT protein, whereas cell lines expressing a low amount of SP1 (D247, GBP44, GBP61) show a low MGMT protein level (Fig. 4d) . To further check the impact of SP1 on the expression of MGMT, SP1 was knocked-down in MGMT expressing T98G cells. The cells showed a strong timedependent decrease in both SP1 and MGMT protein following SP1 siRNA transfection (Fig. 4e) , supporting the notion that SP1 is the main regulator of MGMT expression in glioma cells. To exclude clonal effects, SP1 was knockeddown in the MGMT expressing cell lines LN18 and U118, which also showed decreased MGMT expression following SP1 depletion on protein and RNA level ( Figure S4a and b) .
Interestingly, the human MGMT promoter contains a cluster of nine SP1 binding sites within the last 200 base pairs 5 0 of the MGMT transcription start. On opposite, this cluster is not present in the rat MGMT promoter (Figure S3b for analysis using the Geneions 6.2 software). The high abundance of SP1 binding sites in the human, but not the rat MGMT promoter could provide a reasonable explanation for why MGMT is not inducible in human cells. Thus, the high SP1-triggered basal MGMT expression of the human promoter could overshadow activation signals delivered by other, weaker transcription factors. To test this hypothesis, we checked the inducibility of a SP1 deletion promoter constructs (MGMTDSP1), in which these nine SP1 sites were deleted, after treatment with TMZ, nimustine, and IR. Reduction in the basal MGMT promoter activity by removing SP1 sites rendered the promoter to become inducible following IR exposure in LN229, U87, GBP61, and T98G, but not in LN18 cells (Fig. 5a) . Following nimustine treatment, in T98G cells increased promoter activity was observed (Fig. 5b) , while TMZ had no effect at all on the expression of the MGMT promoter SP1 deletion construct (Fig. 5c) . Overall, the data partially support the notion that the high number of SP1 sites and the high level of SP1 expression in human glioblastoma cells do not allow other transcription factors to enhance the transcription rate and thus hinder the human MGMT promoter from responding in an inducible fashion following genotoxic stress.
Discussion
The DNA repair protein MGMT repairs O 6 -alkylguanine, which is induced by methylating anticancer drugs like TMZ, used in first-line tharapy, and chloroethylnitrosoureas, used in second-line therapy of malignant gliomas (Stupp et al. 2005) . Since lack or low amounts (<30 fmol/mg protein) of MGMT in the tumor enhance the efficiency of therapy (Wiewrodt et al. 2008) , transcriptional activation of MGMT could negatively impact the therapeutic outcome. This is especially important during glioma therapy in which alkylating anticancer drugs are co-administered with ionizing radiation and other pharmaceuticals like glucocorticoids, which are used in order to attenuate inflammation following treatment and during pseudo-progress (Brandsma et al. 2008) . Although in rodent cells, genotoxin-induced transcriptional activation of MGMT has been described more than 20 years ago (Fritz et al. 1991; Fritz and Kaina 1992; Grombacher and Kaina 1995; Grombacher et al. 1996 Grombacher et al. , 1998 Rafferty et al. 1996) , the question concerning inducibility of human MGMT is, despite conflicting reports (Wiewrodt et al. 2008; Kitange et al. 2009) , not yet answered. The human MGMT promoter is regulated on epigenetic level by the presence of 5-methylcytosine, which silences promoter activity (Pieper et al. 1991; Esteller et al. 2000; Hegi et al. 2005) . If the promoter is not epigenetically silenced, it is subject to regulation by a variety of transcription factors. Some of them are involved in gene regulation following genotoxic stress (Christmann and Kaina 2013) .
To analyze whether the human MGMT promoter can be induced (transcriptional upregulated) in human malignant glioblastoma cells, we performed dual luciferase assays and elucidated the regulation of endogenous MGMT on mRNA and protein level. First, we tested potential regulation of the MGMT promoter upon treatment with dexamethasone. In all of the examined glioma cell lines, but not in the cervix carcinoma line HeLa S3, treatment with dexamethasone gave rise to a significant increase in MGMT promoter activity. The MGMT promoter harbors two GREs and is, therefore, a potential target for glucocorticoids provided that the cells are positive for the glucocorticoid receptor. Glucocorticoidmediated up-regulation of the MGMT gene in glioblastoma cells reported here is in line with a previous report (Biswas et al. 1999) . It is important to note that most patients receive high dose dexamethasone or other glucocorticoids after tumor resection and X-ray/temozolomide radiochemotherapy. Therefore, in gliomas with a non-methylated promoter status, a side effect of glucocorticoid therapy might be upregulation of MGMT, which likely has an impact on the efficiency of subsequent adjuvant chemotherapy with temozolomide and nitrosoureas. This might explain the poor outcome of glioblastoma patients who received corticosteroids during chemotherapy (Pitter et al. 2016) .
We also experimented with TPA, a powerful inducer of AP-1 activity and tumor promoter. A slight up-regulation was observed by TPA in LN18, T98G, and HeLa S3 cells. MGMT induction was further analyzed following treatment with TMZ, ACNU, and IR. Although we used a wide dose range and different experimental conditions, the data show that neither the activity of the transfected MGMT promoterreporter construct nor the expression of the endogenous MGMT gene and MGMT enzyme activity was significantly altered. We should mention that in most experiments a weak, but significant induction of the MGMT promoter following treatment with O 6 BG, applied alone or in combination with alkylating drugs, was observed. This may be taken to be indication that the suicide repair reaction of MGMT on the pseudo-substrate O 6 BG, and thereby degradation of MGMT, may trigger its own re-synthesis by an unknown feedback mechanism, which would be worth analyzing in the future.
Several studies suggested that MGMT expression is enhanced in human tumors during therapy. Thus, glioblastoma xenografts showed an increased expression of MGMT upon TMZ treatment of mice (Kitange et al. 2009 ). Furthermore, MGMT activity was found to be higher in recurrences compared to the pre-treatment tumors. This was, however, only found in the tumor group that received temozolomide and not in the radiation-only treated group, indicating up-regulation and selection for high MGMT expressing tumor cells during adjuvant temozolomide therapy (Wiewrodt et al. 2008) . Also in melanoma metastases, MGMT activity was reported to increase during therapy with alkylating agents (Egyhazi et al. 1995 (Egyhazi et al. , 1997 . For melanomas, this might be a consequence of re-activation of silenced MGMT, as reported following chronic treatment with the chloroethylating anticancer drug fotemustine (Christmann et al. 2001) . Of note, selection of pre-existing high MGMTexpressing cells or drug-induced promoter demethylation was also observed in our experiments. Thus, repeated TMZ treatment of MGMT lacking U87 cells gave rise to an up to 200-fold increase in the MGMT mRNA level (Figure S5a-c) . Concomitantly, analyzing promoter methylation by HRM (Switzeny et al. 2016) , a reduced methylation of the promoter was found after repeated TMZ treatment cycles. This again suggests that chronic TMZ treatment leads to selection of cells harboring a weak methylated promoter or to re-activation of the MGMT gene. Selection of pre-existing MGMT-proficient cells could provide an explanation of why NF-jB-and Wnt-dependent induction of MGMT was observed in glioma cells, with MGMT promoter methylated status (Lavon et al. 2007; Wickstrom et al. 2015) .
Besides the question of induction of MGMT by IR and alkylating agents, we also analyzed factors that are supposed to determine the basal level of expression of MGMT. Previously, miR181d was identified as a potential regulator of MGMT in glioblastoma cell lines (Zhang et al. 2012) . Our results revealed only a very weak negative correlation between miR181d and MGMT expression. Furthermore, transfection with mimic miR181d only slightly reduced MGMT expression. Besides miR181d, additional miRNAs such as miR-221 and miR-222, miR-767-3p, miR-603, and miR-648 have been reported to be associated with MGMT expression (Kreth et al. 2013; Quintavalle et al. 2013; Kushwaha et al. 2014) . If miRNAs are critically involved in regulation of MGMT mRNA it would be anticipated that knockdown of the Dicer, which is required for miRNA generation, has an impact on the MGMT mRNA level. This, however, was not the case as knockdown of the Dicer in LN229 cells had only a marginal impact on MGMT expression. This indicates that miRNA-regulated stability of MGMT mRNA might only play a minor role in the basal expression of MGMT in glioma cells.
The expression of MGMT was further reported to depend on the transcription factor p53. Since the MGMT promoter contains no consensus p53 binding sites, the effect of p53 might be attributed to interaction of p53 with SP1. SP1 represents the most abundant transcription factor, which binds to GC boxes in the regulatory region of the gene and is highly important for the basal gene expression level. By molecular interaction, p53 was shown to sequester SP1, which prevents its binding to the MGMT promoter (Costello et al. 1994; Bocangel et al. 2009 ) thus leading to transcriptional repression of the gene. According to this model, the induction of p53 (wild-type) following genotoxic stress, including radiation, temozolomide, and nitrosoureas, might reduce the amount of SP1 molecules per cell and therefore the MGMT expression level. This model could therefore explain the reduced activity of the MGMT promoter upon radiation, observed in our experiments. This notion is confirmed by initial experiments where we observed an enhanced interaction between SP1 and p53 in glioma cells expressing wt p53 upon treatment with IR or TMZ ( Figure S5d ). Since SP1 regulates many other genes, the interaction of SP1 and p53 following genotoxic stress surely deserves attention in future studies.
The importance of SP1 sites in the human MGMT promoter is obvious as we showed that deletion of the SP1 harboring region of the promoter led to a significant (200-400-fold) decrease in the basic promoter activity in glioma cells. Moreover, the expression of SP1 strongly correlates with the expression of MGMT mRNA and protein in glioma cell lines. Finally, knockdown of SP1 strongly reduced MGMT protein expression, showing that SP1 represents the main factor regulating MGMT expression in glioma cells.
It is important to note that the human MGMT promoter contains multiple SP1 binding sites which are missing in the rat MGMT promoter. Therefore, it is reasonable to speculate that the amount of SP1 sites is the underlying reason for the observed differences in the inducibility between the human and rodent MGMT promoter. Of note, MGMT was clearly upregulated following genotoxic stress in rat hepatocytes, which was most obvious in rat liver (Swenberg et al. 1982) and differentiated rat hepatoma cell lines (Grombacher and Kaina 1995) . It was suggested that the common signal triggering the response are DSBs (Fritz and Kaina 1992) . Mouse following whole body irradiation do not show MGMT up-regulation in the liver if p53 was lacking (Rafferty et al. 1996) , which supported a role for p53 in MGMT induction by genotoxic stress. In human cells, the strong SP1 dependence of the MGMT expression could overshadow a possible drug-induced induction. Indeed, as shown here, deletion of SP1 sites in the human promoter rendered the promoter inducible, at least following IR. About 60% of glioblastomas are wild-type for p53 (Jin et al. 2016) . As p53 is induced following radiochemotherapy, including temozolomide (Tomicic et al. 2015), the sequestration of SP1 by p53 may counteract an inducible response triggered by activated AP-1 and NF-kB, and therefore masking an inducible effect (see Fig. 6 ).
Since SP1 represents a key player in MGMT regulation, it might be considered a therapeutic target. Interestingly, the SP1 inhibitor mithramycin A was shown to be therapeutically effective in GBM patients (Ransohoff et al. 1965 ), but was not further clinically used because of its high toxicity. Recent studies showed that mithramycin A induces death in glioma cells via down-regulation of XIAP and reduces cell migration (Seznec et al. 2011 ). In addition, mithramycin A inhibits a SOX2-dependent transcriptional regulatory network, leading to reduced proliferation of GBM cells in vivo. The data warrant further testing of mithramycin A in preclinical GBM models (Singh et al. 2017) . At the same time, our data suggest further experiments addressing the impact of mithramycin A on the expression of MGMT and the toxicity of TMZ in MGMT expressing cells.
In summary, our data support the view that MGMT becomes up-regulated during glucocorticoid treatment. The MGMT status appears not to be altered; however, during radiation and alkylation-based chemotherapy as a result of transcriptional changes of the MGMT gene. Therefore, we conclude that alkylating drug resistance of glioblastoma resulting from transient transcriptional activation of the MGMT gene likely plays only a minor role, while epigenetic changes appear to be more important in MGMT-mediated drug resistance.
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